FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893750600> ?p ?o ?g. }

• W2893750600 endingPage "34055" @default.
• W2893750600 startingPage "34038" @default.
• W2893750600 abstract "// Robert Ramer 1 , Tilman Schmied 1 , Christin Wagner 1 , Maria Haustein 1 and Burkhard Hinz 1 1 Institute of Pharmacology and Toxicology, Rostock University Medical Center, Rostock, Germany Correspondence to: Burkhard Hinz, email: burkhard.hinz@med.uni-rostock.de Keywords: cisplatin; low-dose metronomic treatment; tumor angiogenesis; tissue inhibitor of matrix metalloproteinases-1; lung cancer cells Received: June 20, 2018      Accepted: July 20, 2018      Published: September 25, 2018 ABSTRACT In addition to suppressing cancer cell proliferation and tumor growth, cisplatin has been shown to inhibit tumor angiogenesis. However, the underlying mechanism remains a matter of debate. The present study addressed the impact of cisplatin on potential tumor-to-endothelial cell communication conferring an antiangiogenic effect. For this purpose, migration and tube formation of human umbilical vein endothelial cells (HUVECs) exposed to conditioned media (CM) from vehicle- or cisplatin-treated A549 and H358 lung cancer cells were quantified. Cancer cells were exposed to non-toxic concentrations of cisplatin to mimic low-dose treatment conditions. CM from cancer cells exposed to cisplatin at concentrations of 0.01 to 1 μM elicited a concentration-dependent decrease in HUVEC migration and tube formation as compared with CM from vehicle-treated cells. The viability of HUVECs was virtually unaltered under these conditions. siRNA approaches revealed cisplatin-induced expression and subsequent release of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) by lung cancer cells to be causally linked to a decrease in HUVEC migration and tube formation. Moreover, TIMP-1 upregulation and consequent inhibition of HUVEC migration by cisplatin was shown to be dependent on activation of p38 and p42/44 mitogen-activated protein kinases. Inhibition of angiogenic features was not observed when HUVECs were directly exposed to cisplatin. Similarly, antiangiogenic effects were not detectable in HUVECs exposed to CM from the cisplatin-challenged bronchial non-cancer cell line BEAS-2B. Collectively, the present data suggest a pivotal role of cisplatin-induced TIMP-1 release from lung cancer cells in tumor-to-endothelial cell communication resulting in a reduced cancer-associated angiogenic impact on endothelial cells." @default.
• W2893750600 created "2018-10-05" @default.
• W2893750600 creator A5012277777 @default.
• W2893750600 creator A5023454361 @default.
• W2893750600 creator A5039815661 @default.
• W2893750600 creator A5068726153 @default.
• W2893750600 creator A5088386473 @default.
• W2893750600 date "2018-09-25" @default.
• W2893750600 modified "2023-10-02" @default.
• W2893750600 title "The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells" @default.
• W2893750600 cites W13560890 @default.
• W2893750600 cites W1695090777 @default.
• W2893750600 cites W1974762321 @default.
• W2893750600 cites W1976435333 @default.
• W2893750600 cites W1991277958 @default.
• W2893750600 cites W1993841366 @default.
• W2893750600 cites W1994091018 @default.
• W2893750600 cites W1994183472 @default.
• W2893750600 cites W1995272877 @default.
• W2893750600 cites W1999472716 @default.
• W2893750600 cites W2000292756 @default.
• W2893750600 cites W2008333014 @default.
• W2893750600 cites W2008786326 @default.
• W2893750600 cites W2010413687 @default.
• W2893750600 cites W2012733679 @default.
• W2893750600 cites W2019783342 @default.
• W2893750600 cites W2027629652 @default.
• W2893750600 cites W2032945902 @default.
• W2893750600 cites W2036153305 @default.
• W2893750600 cites W2036561859 @default.
• W2893750600 cites W2049884322 @default.
• W2893750600 cites W2051676630 @default.
• W2893750600 cites W2054979979 @default.
• W2893750600 cites W2055333644 @default.
• W2893750600 cites W2056637878 @default.
• W2893750600 cites W2057812738 @default.
• W2893750600 cites W2069100534 @default.
• W2893750600 cites W2070023824 @default.
• W2893750600 cites W2070098755 @default.
• W2893750600 cites W2070439776 @default.
• W2893750600 cites W2078950638 @default.
• W2893750600 cites W2082886056 @default.
• W2893750600 cites W2083136640 @default.
• W2893750600 cites W2086026895 @default.
• W2893750600 cites W2090806526 @default.
• W2893750600 cites W2092743430 @default.
• W2893750600 cites W2100093357 @default.
• W2893750600 cites W2110554273 @default.
• W2893750600 cites W2114733293 @default.
• W2893750600 cites W2115359735 @default.
• W2893750600 cites W2148530063 @default.
• W2893750600 cites W2157000986 @default.
• W2893750600 cites W2159365419 @default.
• W2893750600 cites W2160589892 @default.
• W2893750600 cites W2167717055 @default.
• W2893750600 cites W2169965478 @default.
• W2893750600 cites W2276640105 @default.
• W2893750600 cites W2297085520 @default.
• W2893750600 cites W2302469444 @default.
• W2893750600 cites W2408051866 @default.
• W2893750600 cites W2471671636 @default.
• W2893750600 cites W2518682401 @default.
• W2893750600 cites W2531561799 @default.
• W2893750600 cites W2566863750 @default.
• W2893750600 cites W2596008862 @default.
• W2893750600 cites W2601082158 @default.
• W2893750600 cites W4238673197 @default.
• W2893750600 cites W2488225970 @default.
• W2893750600 doi "https://doi.org/10.18632/oncotarget.25954" @default.
• W2893750600 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6183343" @default.
• W2893750600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30344920" @default.
• W2893750600 hasPublicationYear "2018" @default.
• W2893750600 type Work @default.
• W2893750600 sameAs 2893750600 @default.
• W2893750600 citedByCount "24" @default.
• W2893750600 countsByYear W28937506002019 @default.
• W2893750600 countsByYear W28937506002020 @default.
• W2893750600 countsByYear W28937506002021 @default.
• W2893750600 countsByYear W28937506002022 @default.
• W2893750600 countsByYear W28937506002023 @default.
• W2893750600 crossrefType "journal-article" @default.
• W2893750600 hasAuthorship W2893750600A5012277777 @default.
• W2893750600 hasAuthorship W2893750600A5023454361 @default.
• W2893750600 hasAuthorship W2893750600A5039815661 @default.
• W2893750600 hasAuthorship W2893750600A5068726153 @default.
• W2893750600 hasAuthorship W2893750600A5088386473 @default.
• W2893750600 hasBestOaLocation W28937506001 @default.
• W2893750600 hasConcept C109523444 @default.
• W2893750600 hasConcept C121608353 @default.
• W2893750600 hasConcept C126322002 @default.
• W2893750600 hasConcept C142724271 @default.
• W2893750600 hasConcept C185592680 @default.
• W2893750600 hasConcept C202751555 @default.
• W2893750600 hasConcept C2776256026 @default.
• W2893750600 hasConcept C2776694085 @default.
• W2893750600 hasConcept C2777411675 @default.
• W2893750600 hasConcept C2778239845 @default.
• W2893750600 hasConcept C2780394083 @default.

• next